drugset / Trial / NCT00625495

Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)

NCT00625495

Phase 4 Completed 60 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to examine the effects of Nexium at a dose of 40mg administered orally compared to intravenously on the maximum acid output in subjects with symptoms of Gastroesophageal reflux disease (GERD).

Timeline

Start
2002-09
Primary completion
2002-11
Completion
2002-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 40 mg Intravenous